XORTX Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

XORTX Therapeutics şirketinin toplam hissedar öz sermayesi $2.1M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $3.9M ve $1.7M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$2.30m
Eşitlik	US$2.13m
Toplam yükümlülükler	US$1.72m
Toplam varlıklar	US$3.85m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: XRTX 'nin kısa vadeli varlıkları ( $2.4M ) kısa vadeli yükümlülüklerini ( $387.8K ) aşıyor.

Uzun Vadeli Yükümlülükler: XRTX şirketinin kısa vadeli varlıkları ( $2.4M ) uzun vadeli yükümlülüklerini ( $1.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: XRTX borçsuzdur.

Borcun Azaltılması: XRTX şu anda borcu yok ancak 5 yıl öncesine ait verimiz olmadığı için karşılaştırma yapamıyoruz.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: XRTX son raporlanan serbest nakit akışına göre 7 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: XRTX serbest nakit akışı tahminlerine göre 6 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

XORTX Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

XORTX Therapeutics Inc. announced delayed 20-F filing

XORTX Therapeutics to Consider A Consolidation of the Company’s Issued and Outstanding Shares in Order for the Company to Regain Compliance with the Continued Listing Requirements for the Nasdaq Capital Market

XORTX Therapeutics Provides Nasdaq Compliance Update

XORTX Therapeutics Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

XORTX Therapeutics Inc. announced delayed 20-F filing

Recent updates

New major risk - Shareholder dilution

XORTX Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $1.499994 million.

XORTX Therapeutics Inc. Initiates Precision Medicine Program

New major risk - Share price stability

XORTX Therapeutics Inc. announced delayed 20-F filing

XORTX Therapeutics Inc. Appoints Abigail Jenkins to the Board of Directors

XORTX Therapeutics Inc. Appoints Ronald Perrone as Clinical Advisory Board

XORTX Therapeutics Inc. announced a financing transaction

High number of new and inexperienced directors

XORTX Therapeutics Inc. Announces Board Changes

XORTX Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $3.701931 million.

New major risk - Revenue and earnings growth

XORTX Therapeutics Inc. Announces Presentation of New Research Findings At the American Society of Nephrology Meeting

XORTX Therapeutics to Consider A Consolidation of the Company’s Issued and Outstanding Shares in Order for the Company to Regain Compliance with the Continued Listing Requirements for the Nasdaq Capital Market

XORTX Therapeutics Provides Nasdaq Compliance Update

New major risk - Share price stability

Xortx Therapeutics Inc. Submits Orphan Drug Designation Application to the European Medicines Agency to Treat Progressive Kidney Disease

New major risk - Market cap size

XORTX Therapeutics Inc. Announces Chief Financial Officer Changes

XORTX Therapeutics Inc. Announces Departure of Jacqueline Le Saux

XORTX Therapeutics Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

XORTX Therapeutics Inc. Announces FDA Confirms Eligibility of XORLO™ for Accelerated Approval

XORTX Therapeutics Inc. Announces Goals for 2023

Xortx Therapeutics Inc. Announces Submission of Orphan Drug Designation Request for Xrx-008 Program to Treat Autosomal Dominant Kidney Disease

XORTX Therapeutics Inc. Announces Positive Topline Results from XRX-OXY-101 Clinical Trial

XORTX Therapeutics Inc Files New Provisional Patent to Diagnose and Treat Individuals Most at Risk of Polycystic Kidney Disease Progression

XORTX Therapeutics Inc. Announces Completion of Dosing in XRX-OXY-101 Clinical Study

XORTX Therapeutics Inc. Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease

XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study

XORTX Therapeutics Appoints Stacy Evans as Chief Business Officer

High number of new and inexperienced directors

XORTX Therapeutics Inc. Receives Further No Objection Letter from Health Canada

XORTX Therapeutics Inc. has completed a Composite Units Offering in the amount of $4.99964 million.

XORTX Therapeutics Inc. Completes Positive Pre-Phase 3 Meeting with the US Food and Drug Administration

XORTX completes positive pre-phase 3 meeting with the FDA

XORTX Therapeutics Inc. Announces Positive Topline Results from Part 2 Pharmacokinetics Bridging Study

Xortx stock soars 40% as kidney disease drug shows promise in bridging study

High number of new and inexperienced directors

XORTX Therapeutics Inc. Announces Submission to European Medicines Agency

XORTX Therapeutics Inc. Announces Positive Topline Results from Pharmacokinetics Bridging Clinical Trial

XORTX jumps over 100% after early encouraging data for rare disease therapy

XORTX Announces Pre-Phase 3 Meeting Request with US Food and Drug Administration (FDA)

XORTX Therapeutics Inc. Appoints Anthony Giovinazzo to the Board of Directors and as Chair of the Board

XORTX Therapeutics Inc., Annual General Meeting, Jul 20, 2022

XORTX Therapeutics Inc. Opens an IND for XRx-008 Program for Autosomal Dominant Polycystic Kidney Disease

XORTX Therapeutics Inc. Initiates Dosing of Human Subjects in the Xrx-Oxy-101 Clinical Trial

XORTX Therapeutics Inc. announced delayed 20-F filing

High number of new and inexperienced directors

XORTX Therapeutics Inc. Receives No Objection Letter from Health Canada

XORTX Therapeutics Inc. Announces Grant of US Patent

Xortx Therapeutics Inc. Announces Filing of an Investigational New Drug Application with the Unites States Food and Drug Administration

XORTX Therapeutics Inc. Provides Corporate Update for 2022

XORTX Therapeutics Announces Filing of Provision Patent for Polycystic Kidney Disease

XORTX Therapeutics Inc. Announces Publication of Mt. Sinai Study of Hospitalized COVID-19 Patients

High number of new and inexperienced directors

XORTX Therapeutics Inc., Annual General Meeting, Apr 29, 2021

XORTX Therapeutics Inc. Announces the Filing of A New Provisional Patent Application Entitled "Compositions and Methods for Enhancing Anti-Viral Therapies"

XORTX Therapeutics Inc. announced that it has received CAD 6.121572 million in funding

XORTX Therapeutics Inc. announced that it expects to receive CAD 3 million in funding

XORTX Announces Grant of European Patent

XORTX Therapeutics Inc. Announces Topline Results from Mount Sinai’s COVID-19 Clinical Study

XORTX Therapeutics Inc. Receives Positive Feedback from FDA on COVID-19 Related Acute Kidney Injury

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin